C. Hudis

982 total citations
19 papers, 268 citations indexed

About

C. Hudis is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Hudis has authored 19 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Hudis's work include Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (5 papers). C. Hudis is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (5 papers). C. Hudis collaborates with scholars based in United States, Palestinian Territory and Italy. C. Hudis's co-authors include Monica Fornier, David P. Kelsen, Larry Norton, Eileen M. O’Reilly, Manisha H. Shah, Robert A. Lefkowitz, Archie Tse, S. Patil, Dana E. Rathkopf and Gary K. Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

C. Hudis

16 papers receiving 262 citations

Peers

Countries citing papers authored by C. Hudis

Since Specialization

Citations

This map shows the geographic impact of C. Hudis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Hudis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Hudis more than expected).

Fields of papers citing papers by C. Hudis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Hudis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Hudis. The network helps show where C. Hudis may publish in the future.

Co-authorship network of co-authors of C. Hudis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Hudis. A scholar is included among the top collaborators of C. Hudis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Hudis. C. Hudis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Molecular determinants of post-mastectomy breast cancer recurrence 2018 ·npj Breast Cancer ·K.S. Keene, Tari A. King, E. Shelley Hwang, Bo Peng, Kandace P. McGuire, Coya Tapia, Hong Zhang, Sejong Bae, Faina Nakhlis, Nancy Klauber‐DeMore, Ingrid M. Meszoely, Michael S. Sabel, Shawna C. Willey, Agda Karina Eterovic, C. Hudis, Antonio C. Wolff, Jennifer De Los Santos, Alastair M. Thompson, Gordon B. Mills, Funda Meric‐Bernstam	9
2	Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy 2016 ·Annals of Oncology ·Neil M. Iyengar, Lillian M. Smyth, Diana Lake, Ayca Gucalp, (unknown), (unknown), Patricia DeFusco, (unknown), Monica Fornier, Shari Goldfarb, Komal Jhaveri, Asma Latif, Shanu Modi, Tiffany A. Troso-Sandoval, Gary A. Ulaner, Maxine S. Jochelson, José Baselga, Larry Norton, C. Hudis, Chau T. Dang	2
3	Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy 2015 ·Cancer Research ·Devika Gajria, Shanu Modi, Cristina Saura, Rita A. Sakr, (unknown), Helen Won, Harpreet K. Pannu, Sujata Patil, Diana Lake, Tiffany A. Traina, Tari A. King, Michael F. Berger, José Baselga, Neal Rosen, C. Hudis, Sarat Chandarlapaty	5
4	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study 2014 ·Molecular Oncology ·Leonardo Tenori, Catherine Oakman, Patrick G. Morris, (unknown), Natalie Turner, Silvia Cappadona, Monica Fornier, C. Hudis, Larry Norton, Claudio Luchinat, Angelo Di Leo	80
5	Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017 2014 ·Annals of Surgical Oncology ·Kandace P. McGuire, E. Shelley Hwang, Alan Cantor, Mehra Golshan, Funda Meric‐Bernstam, Janet K. Horton, Rita Nanda, Keith D. Amos, Andres Forero, C. Hudis, Ingrid M. Meszoely, Jennifer F. De Los Santos	10
6	Abstract P5-18-04: Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer 2012 ·Cancer Research ·Devika Gajria, Tari A. King, Harpreet K. Pannu, Rita A. Sakr, Shanu Modi, Pamela Drullinsky, (unknown), Sujata Patil, Andrew D. Seidman, Larry Norton, Neal Rosen, C. Hudis, Sarat Chandarlapaty	2
7	Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays 2011 ·Annals of Oncology ·Edi Brogi, Conleth G. Murphy, Matthew Johnson, Alison Conlin, Melinda Laine Hsu, Sujata Patil, (unknown), (unknown), Komal Jhaveri, C. Hudis, A. D. Seidman	30
8	Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database. 2011 ·Journal of Clinical Oncology ·Jonathan L. Vandergrift, Joyce C. Niland, Richard L. Theriault, (unknown), Yut-Lin Wong, Loretta Loftus, (unknown), C. Hudis, (unknown), H. S. Rugo, (unknown), Eva M. Lepisto, (unknown)	1
9	Abstract P2-14-08: Patient Perspectives on Information Communicated Regarding Effects of Treatment on Fertility 2010 ·Cancer Research ·(unknown), (unknown), Bridgette Thom, Jennifer B. Kaplan, (unknown), (unknown), (unknown), Larry Norton, C. Hudis, Ethan Basch, (unknown)	0
10	Oncology physicians' knowledge, attitudes, and practices regarding fertility preservation. 2010 ·Journal of Clinical Oncology ·Shari Goldfarb, Maura N. Dickler, Mary S. McCabe, Bridgette Thom, (unknown), C. Hudis, Ethan Basch, Joanne Frankel Kelvin	7
11	Breast Cancer Risk Single Nucleotide Polymorphism (SNP) Genotypes Do Not Correlate with Risk Estimates from Existing Prediction Models. 2009 ·Cancer Research ·Elizabeth Comen, (unknown), Tomas Kirchhoff, Mia M. Gaudet, (unknown), C. Hudis, Kenneth Offit, Mark E. Robson	1
12	Use of multiplex mutation genotyping to identify novel and protective mutations in breast cancer 2009 ·Journal of Clinical Oncology ·Kevin Kalinsky, Lindsay M. Jacks, Cyrus V. Hedvat, Umesh Bhanot, (unknown), Adriana Heguy, Marina Asher, Marija Drobnjak, C. Hudis, Mary Ellen Moynahan	0
13	Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety 2007 ·Journal of Clinical Oncology ·Maura N. Dickler, (unknown), K. Panageas, Richard M. Steingart, Chau T. Dang, Monica Fornier, S. Sugarman, Larry Norton, C. Hudis, Hope S. Rugo	5
14	Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors 2007 ·Clinical Cancer Research ·Monica Fornier, Dana E. Rathkopf, Manisha H. Shah, S. Patil, Eileen M. O’Reilly, Archie Tse, C. Hudis, Robert A. Lefkowitz, David P. Kelsen, Gary K. Schwartz	76
15	Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) 2006 ·Journal of Clinical Oncology ·(unknown), Hope S. Rugo, James F. Caravelli, Benjamin M. Yeh, K. Panageas, (unknown), Larry Norton, (unknown), C. Hudis, (unknown)	22
16	Serum peptide profiling (SPP) by mass spectrometry (MS) to identify post-menopausal women with metastatic breast cancer 2005 ·Journal of Clinical Oncology ·Karen L. Smith, Josep Villanueva, Gabriella D’Andrea, Mary Ellen Moynahan, Nancy T. Sklarin, Larry Norton, C. Hudis, Paul Tempst, Mark E. Robson	1
17	Decreasing tumor size explains some improvement in survival from localized breast cancer 2004 ·Journal of Clinical Oncology ·Elena B. Elkin, Deborah Schrag, C. Hudis, (unknown)	0
18	Dose-dense paclitaxel-containing adjuvant therapy for breast cancer. 1998 ·PubMed ·C. Hudis	4
19	Menogaril in the treatment of malignant mesothelioma: A phase II study 1992 ·Investigational New Drugs ·C. Hudis, David P. Kelsen	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact